verapamil has been researched along with Acute Confusional Senile Dementia in 79 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral treatment with verapamil or vehicle was started, 24 h post-intracerebroventricular (ICV) streptozotocin/(STZ), in 12-month-old animals and continued for 3 months." | 1.62 | Verapamil Prevents Development of Cognitive Impairment in an Aged Mouse Model of Sporadic Alzheimer's Disease. ( Ahmed, HA; Ishrat, T; Ismael, S; Mirzahosseini, G, 2021) |
| "In the brains of patients with Alzheimer's disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased." | 1.46 | N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents. ( Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A, 2017) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | 1.42 | Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| "Alzheimer's disease is the most common cause of dementia." | 1.42 | In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| " This led to the identification of selected triazolopyrimidines and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function." | 1.40 | Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies. ( Ballatore, C; Brunden, KR; Cornec, AS; Gay, B; Hoye, AT; Hyde, E; James, MJ; Lee, VM; Lou, K; Smith, AB; Trojanowski, JQ; Yao, Y, 2014) |
| "A major pathological hallmark of Alzheimer's disease is accumulation of amyloid-β in senile plaques in the brain." | 1.38 | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. ( Bauer, M; Comans, EF; Hoetjes, NJ; Lammertsma, AA; Langer, O; Lubberink, M; Müller, M; Scheltens, P; Schuit, RC; Tolboom, N; van Assema, DM; van Berckel, BN; van der Flier, WM; Windhorst, AD, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.33) | 18.2507 |
| 2000's | 4 (5.06) | 29.6817 |
| 2010's | 57 (72.15) | 24.3611 |
| 2020's | 13 (16.46) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 3 |
| Andrisano, V | 4 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 3 |
| Rodríguez-Franco, MI | 6 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 3 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 2 |
| Badia, A | 1 |
| Clos, MV | 2 |
| Mancini, F | 2 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 4 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Chiriano, G | 1 |
| De Simone, A | 2 |
| Perez, DI | 2 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Carloni, P | 1 |
| Roberti, M | 1 |
| Sun, Y | 2 |
| Chen, J | 1 |
| Chen, X | 1 |
| Huang, L | 3 |
| Li, X | 4 |
| Lou, K | 1 |
| Yao, Y | 1 |
| Hoye, AT | 1 |
| James, MJ | 1 |
| Cornec, AS | 1 |
| Hyde, E | 1 |
| Gay, B | 1 |
| Lee, VM | 1 |
| Trojanowski, JQ | 1 |
| Smith, AB | 1 |
| Brunden, KR | 1 |
| Ballatore, C | 1 |
| Di Pietro, O | 1 |
| Pérez-Areales, FJ | 2 |
| Juárez-Jiménez, J | 1 |
| Espargaró, A | 2 |
| Pérez, B | 3 |
| Sabaté, R | 2 |
| Miao, H | 1 |
| Meng, F | 1 |
| Lan, JS | 7 |
| Xie, SS | 8 |
| Li, SY | 1 |
| Pan, LF | 1 |
| Wang, XB | 10 |
| Kong, LY | 12 |
| Huang, M | 1 |
| Jiang, N | 5 |
| Sang, Z | 12 |
| Li, Y | 11 |
| Qiang, X | 10 |
| Xiao, G | 7 |
| Liu, Q | 2 |
| Tan, Z | 12 |
| Deng, Y | 11 |
| Dong, G | 1 |
| Li, ZR | 2 |
| Wang, KD | 2 |
| Guo, PP | 1 |
| Wang, X | 3 |
| Yu, W | 1 |
| Więckowska, A | 3 |
| Więckowski, K | 2 |
| Bajda, M | 1 |
| Brus, B | 2 |
| Sałat, K | 1 |
| Czerwińska, P | 1 |
| Gobec, S | 4 |
| Filipek, B | 1 |
| Malawska, B | 3 |
| Cahlíková, L | 1 |
| Štěpánková, Š | 1 |
| Chlebek, J | 1 |
| Šafratová, M | 1 |
| Hošt'álková, A | 1 |
| Opletal, L | 1 |
| Wang, ZM | 3 |
| Li, F | 5 |
| Wu, JJ | 6 |
| Wang, J | 5 |
| Pan, W | 3 |
| Hu, K | 1 |
| Bai, P | 3 |
| Yu, L | 5 |
| Ma, Q | 5 |
| Li, T | 1 |
| Zhang, X | 3 |
| Chen, C | 1 |
| Peng, K | 1 |
| Liu, W | 12 |
| Luo, L | 6 |
| Li, XM | 1 |
| Cai, P | 6 |
| Liu, QH | 5 |
| Xu, DQ | 1 |
| Yang, XL | 6 |
| Kołaczkowski, M | 1 |
| Bucki, A | 1 |
| Godyń, J | 2 |
| Marcinkowska, M | 1 |
| Zaręba, P | 1 |
| Siwek, A | 1 |
| Kazek, G | 1 |
| Głuch-Lutwin, M | 1 |
| Mierzejewski, P | 1 |
| Bienkowski, P | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Knez, D | 3 |
| Wichur, T | 1 |
| Košak, U | 1 |
| Coquelle, N | 1 |
| Pišlar, A | 1 |
| Nachon, F | 1 |
| Brazzolotto, X | 2 |
| Kos, J | 1 |
| Colletier, JP | 1 |
| Yang, X | 5 |
| Zheng, Y | 4 |
| Cao, Z | 6 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 5 |
| Song, Q | 5 |
| Xia, CL | 1 |
| Wang, N | 1 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Huang, SL | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 1 |
| Huang, ZS | 1 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Wang, K | 8 |
| Yang, Y | 1 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Zhang, T | 2 |
| Liu, Y | 2 |
| Yang, J | 3 |
| Liu, J | 2 |
| Miao, ZY | 1 |
| Ding, Y | 2 |
| Yang, HL | 3 |
| Kang, P | 1 |
| Hou, JW | 1 |
| Zhang, XY | 1 |
| Fang, SQ | 1 |
| Tang, YW | 2 |
| Wang, C | 2 |
| Wang, H | 4 |
| Ye, M | 2 |
| Han, X | 2 |
| Huang, Q | 1 |
| Liang, N | 1 |
| Li, Q | 3 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Kumar, D | 1 |
| Gupta, SK | 1 |
| Ganeshpurkar, A | 1 |
| Gutti, G | 1 |
| Krishnamurthy, S | 1 |
| Modi, G | 1 |
| Singh, SK | 1 |
| Reis, J | 1 |
| Cagide, F | 1 |
| Valencia, ME | 1 |
| Teixeira, J | 1 |
| Bagetta, D | 1 |
| Uriarte, E | 1 |
| Oliveira, PJ | 1 |
| Ortuso, F | 1 |
| Alcaro, S | 1 |
| Borges, F | 1 |
| Tian, C | 1 |
| Shi, CJ | 1 |
| Hu, J | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Li, W | 1 |
| He, Y | 1 |
| Ye, C | 1 |
| Shi, J | 4 |
| Srivastava, P | 1 |
| Tripathi, PN | 1 |
| Sharma, P | 1 |
| Shrivastava, SK | 1 |
| Zhang, P | 3 |
| Turcu, AL | 2 |
| Barniol-Xicota, M | 1 |
| Pont, C | 1 |
| Pivetta, D | 1 |
| Sureda, FX | 2 |
| Vázquez, S | 2 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Jiang, X | 3 |
| Zhou, J | 1 |
| Wang, Y | 4 |
| Chen, L | 2 |
| Duan, Y | 1 |
| Huang, J | 1 |
| Liu, C | 2 |
| Chen, Y | 2 |
| Sun, H | 3 |
| Feng, F | 2 |
| Qu, W | 1 |
| Xing, C | 1 |
| Lyu, W | 1 |
| Wang, S | 1 |
| Chen, T | 1 |
| Pasieka, A | 1 |
| Panek, D | 1 |
| Jończyk, J | 1 |
| Szałaj, N | 1 |
| Latacz, G | 1 |
| Tabor, J | 1 |
| Mezeiova, E | 1 |
| Chantegreil, F | 1 |
| Dias, J | 1 |
| Lu, J | 1 |
| Pi, R | 1 |
| Korabecny, J | 1 |
| Höfner, G | 1 |
| Wanner, K | 1 |
| Qu, L | 1 |
| Ji, L | 1 |
| Luo, H | 1 |
| Li, S | 1 |
| Peng, W | 1 |
| Yin, F | 1 |
| Lu, D | 1 |
| Liu, X | 2 |
| Kong, L | 1 |
| Tian, L | 1 |
| Gao, Y | 1 |
| Chen, H | 1 |
| Xu, Z | 1 |
| Ding, H | 1 |
| Zhao, Q | 1 |
| Xi, M | 1 |
| Feng, C | 1 |
| Du, K | 1 |
| Lv, W | 1 |
| Du, C | 1 |
| Shen, R | 1 |
| Sun, X | 1 |
| Lei, Z | 1 |
| Yue, S | 1 |
| Sun, J | 1 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Soto, D | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Boboc, IKS | 1 |
| Cojocaru, A | 1 |
| Nedelea, G | 1 |
| Catalin, B | 1 |
| Bogdan, M | 1 |
| Calina, D | 1 |
| Ponne, S | 1 |
| Kumar, CR | 1 |
| Boopathy, R | 1 |
| Nikpour, M | 1 |
| Sharafi, A | 1 |
| Hamidi, M | 1 |
| Andalib, S | 1 |
| Storelli, F | 1 |
| Billington, S | 1 |
| Kumar, AR | 1 |
| Unadkat, JD | 2 |
| Ahmed, HA | 1 |
| Ismael, S | 1 |
| Mirzahosseini, G | 1 |
| Ishrat, T | 1 |
| Mehta, DC | 1 |
| Short, JL | 1 |
| Nicolazzo, JA | 1 |
| Deo, AK | 1 |
| Borson, S | 1 |
| Link, JM | 1 |
| Domino, K | 1 |
| Eary, JF | 1 |
| Ke, B | 1 |
| Richards, TL | 1 |
| Mankoff, DA | 1 |
| Minoshima, S | 1 |
| O'Sullivan, F | 1 |
| Eyal, S | 1 |
| Hsiao, P | 1 |
| Maravilla, K | 1 |
| Ghayur, MN | 1 |
| Gilani, AH | 1 |
| Ahmed, T | 1 |
| Khalid, A | 1 |
| Nawaz, SA | 1 |
| Agbedahunsi, JM | 1 |
| Choudhary, MI | 1 |
| Houghton, PJ | 1 |
| Abuznait, AH | 1 |
| Cain, C | 1 |
| Ingram, D | 1 |
| Burk, D | 1 |
| Kaddoumi, A | 1 |
| van Assema, DM | 2 |
| Lubberink, M | 2 |
| Bauer, M | 1 |
| van der Flier, WM | 2 |
| Schuit, RC | 1 |
| Windhorst, AD | 2 |
| Comans, EF | 1 |
| Hoetjes, NJ | 1 |
| Tolboom, N | 1 |
| Langer, O | 1 |
| Müller, M | 1 |
| Scheltens, P | 2 |
| Lammertsma, AA | 2 |
| van Berckel, BN | 2 |
| Goos, JD | 1 |
| Boellaard, R | 1 |
| Sen, AP | 1 |
| Boksa, P | 1 |
| Quirion, R | 1 |
| Popović, M | 2 |
| Popović, N | 2 |
| Jovanova-Nesić, K | 1 |
| Bokonjić, D | 2 |
| Dobrić, S | 2 |
| Kostić, VS | 1 |
| Rosić, N | 1 |
| Crawford, F | 1 |
| Suo, Z | 1 |
| Fang, C | 1 |
| Mullan, M | 1 |
| Caballero-Bleda, M | 1 |
| Kotake, H | 1 |
| Hisatome, I | 1 |
| Matsuoka, S | 1 |
| Miyakoda, H | 1 |
| Hasegawa, J | 1 |
| Mashiba, H | 1 |
79 other studies available for verapamil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
Topics: Administration, Oral; Alzheimer Disease; Animals; Biological Availability; Brain; Cell Line; Humans; | 2014 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2014 |
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line, Tu | 2015 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.
Topics: Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Blood-Brain Barrier; Cell Survival; Ch | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrie | 2015 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chol | 2016 |
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alkanes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Chemi | 2016 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2016 |
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cataly | 2016 |
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cell Death; Cell Line; Cholinestera | 2017 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Bra | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relations | 2017 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell L | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Dimerization; Humans; Mice | 2019 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stres | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inh | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2021 |
Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Dru | 2021 |
Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Antioxidants; Aspart | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyr | 2021 |
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cell Survival; Cholineste | 2022 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites | 2022 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Chronic Administration of Ion Channel Blockers Impact Microglia Morphology and Function in a Murine Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Carbamazepine; Di | 2023 |
Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury - A potential therapeutic agent for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Avoidance Learning; Brain; Cell Line, Tumor; Cell | 2020 |
Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Aquaporin 1; ATP Binding Cassette Transporter, Subfamily B; Disease Mode | 2020 |
Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; ATP Binding C | 2021 |
Verapamil Prevents Development of Cognitive Impairment in an Aged Mouse Model of Sporadic Alzheimer's Disease.
Topics: Aging; Alzheimer Disease; Animals; Brain; Calcium Channel Blockers; Cognitive Dysfunction; Disease M | 2021 |
Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Tran | 2013 |
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease.
Topics: Adult; Aged; Alzheimer Disease; Amyloid beta-Peptides; ATP Binding Cassette Transporter, Subfamily B | 2014 |
Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia.
Topics: Acetylcholine; Alzheimer Disease; Animals; Atropine; Butyrylcholinesterase; Calcium; Calcium Channel | 2008 |
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; ATP Binding Cassette Transporter, Subfamily B, Member 1; C | 2011 |
Blood-brain barrier P-glycoprotein function in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrie | 2012 |
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.
Topics: Aged; Alzheimer Disease; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrie | 2012 |
Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases.
Topics: Aged; Alzheimer Disease; Autopsy; Binding Sites; Brain; Calcium; Calcium Channels; Dihydropyridines; | 1993 |
Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Basal Ganglia; Brain; Calcium Channel Blockers; Chol | 1997 |
Characteristics of the in vitro vasoactivity of beta-amyloid peptides.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aorta; Calcimycin; Calcium Channel Blockers; Calc | 1998 |
Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats.
Topics: Aggression; Alzheimer Disease; Animals; Avoidance Learning; Calcium Channel Blockers; Cognition Diso | 1997 |
Inhibitory effect of 9-amino-1,2,3,4-tetrahydroacridine (THA) on the potassium current of rabbit sinoatrial node.
Topics: Alzheimer Disease; Aminoacridines; Animals; Female; Ion Channel Gating; Male; Potassium Channels; Ra | 1990 |